Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Human Papillomavirus | Research

Dynamic change of the systemic immune inflammation index is a risk factor for patients with oropharyngeal cancer: a case control study and an additional HPV-status subgroup analysis

Authors: XiaoChuan Gan, QiTao Gou, Jing Zhu, Tao Zhang

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

The study aimed to analyze the relationship between the dynamic systemic immune inflammation index (SII), human papillomavirus (HPV) infection, and the prognosis of oropharyngeal cancer patients.

Method

We retrospectively obtained the data for 131 patients treated with curative treatments and calculated their SII values based on results acquired approximately 9 months after the first treatment. The entire cohort was divided into groups according to dynamic SII and HPV infection, and their prognoses were compared.

Results

The high SII group, particularly the persistently high SII group, had a poor prognosis, and static SII levels cannot fully reflect the prognosis of patients with oropharyngeal cancer. In HPV− patients, unfavorable dynamic SII and the site of tumor locating at the tongue base were all significantly associated with decreased disease-free survival. In contrast, no characteristic was presented as a poor prognostic factor for disease-free or overall survival in HPV+ patients.

Conclusion

Dynamic SII values are more comprehensive prognostic indicators for oropharyngeal cancer patients, particularly HPV− patients. It could imply that an HPV− oropharyngeal cancer patient who experienced unfavorable dynamic changes in SII should receive more frequent tests or more advanced therapies.

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.CrossRefPubMed

Machczyński P, Majchrzak E, Niewinski P, Marchlewska J, Golusiński W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Oto-Rhino-Laryngol. 2020;277(9):2407–12.CrossRef

Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):571–8.CrossRefPubMed

Brewczynski A, Jablonska B, Mazurek AM, Mrochem-Kwarciak J, Mrowiec S, Snietura M, et al. Comparison of selected immune and hematological parameters and their impact on survival in patients with HPV-related and HPV-unrelated oropharyngeal cancer. Cancers (Basel). 2021;13(13):3256.CrossRefPubMed

Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050–8.CrossRefPubMedPubMedCentral

Golusinski P, Corry J, Poorten VV, Simo R, Sjögren E, Mäkitie A, et al. De-escalation studies in HPV-positive oropharyngeal cancer: how should we proceed? Oral Oncol. 2021;123:105620.CrossRefPubMed

Rahimi S. HPV-related squamous cell carcinoma of oropharynx: a review. J Clin Pathol. 2020;73(10):624–9.CrossRefPubMed

Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39(9):956–65.CrossRefPubMedPubMedCentral

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefPubMedPubMedCentral

10.

Huang SH, Waldron JN, Milosevic M, Shen X, Ringash J, Su J, et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015;121(4):545–55.CrossRefPubMed

11.

Meshman J, Velez MA, Wang PC, Abemayor E, St John M, Wong D, et al. Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status. Oral Oncol. 2019;89:121–6.CrossRefPubMed

12.

Takahashi H, Sakakura K, Tada H, Kaira K, Oyama T, Chikamatsu K. Prognostic significance and population dynamics of peripheral monocytes in patients with oropharyngeal squamous cell carcinoma. Head Neck. 2019;41(6):1880–8.CrossRefPubMed

13.

Kano S, Homma A, Hatakeyama H, Mizumachi T, Sakashita T, Kakizaki T, et al. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. Head Neck. 2017;39(2):247–53.CrossRefPubMed

14.

Rachidi S, Wallace K, Wrangle JM, Day TA, Alberg AJ, Li Z. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1068–74.CrossRefPubMed

15.

Hung SP, Chen PR, Ho TY, Chang KP, Chou WC, Lee CH, et al. Prognostic significance of the preoperative systemic immune-inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy. Cancer Med. 2021;10(2):649–58.CrossRefPubMed

16.

Li Z, Qu Y, Yang Y, An W, Li S, Wang B, et al. Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma. Clin Otolaryngol. 2021;46(2):395–405.CrossRefPubMed

17.

Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, et al. Systemic Immune-Inflammation Index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–8.CrossRefPubMed

18.

Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol. 2019;234(5):5555–63.CrossRefPubMed

19.

Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284.CrossRefPubMedPubMedCentral

20.

Zhang W, Wang R, Ma W, Wu Y, Maskey N, Guo Y, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.CrossRefPubMedPubMedCentral

21.

Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.CrossRefPubMed

22.

Wurdemann N, Wagner S, Sharma SJ, Prigge ES, Reuschenbach M, Gattenlohner S, et al. Prognostic impact of AJCC/UICC 8th edition new staging rules in oropharyngeal squamous cell carcinoma. Front Oncol. 2017;7:129.CrossRefPubMedPubMedCentral

23.

Mallen-St Clair J, Ho AS. American Joint Committee on Cancer 8(th) edition staging-an improvement in prognostication in HPV-associated oropharyngeal cancer? Ann Transl Med. 2019;7(Suppl 1):S10.CrossRefPubMedPubMedCentral

24.

Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24.CrossRefPubMed

25.

Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–95.CrossRefPubMedPubMedCentral

26.

Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 2011;104(5):504–10.CrossRefPubMed

27.

Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48(2):202–8.CrossRefPubMed

28.

Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54(5):948–55.CrossRefPubMed

29.

Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901–7.CrossRefPubMedPubMedCentral

30.

Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62(3):471–9.CrossRefPubMed

31.

Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103(3):481–90.CrossRefPubMedPubMedCentral

32.

Kono H, Fujii H, Ogiku M, Hosomura N, Amemiya H, Tsuchiya M, et al. Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice. J Immunol. 2011;187(9):4818–25.CrossRefPubMed

33.

Kusumanto YH, Dam WA, Hospers GAP, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–7.CrossRefPubMed

34.

Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33(6):965–83.CrossRefPubMedPubMedCentral

35.

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22.CrossRefPubMedPubMedCentral

36.

Chatfield-Reed K, Gui S, O’Neill WQ, Teknos TN, Pan Q. HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes. Oral Oncol. 2020;100:104488.CrossRefPubMed

37.

Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, et al. NCCN Guidelines(R) insights: head and neck cancers, Version 1. 2022. J Natl Compr Cancer Netw. 2022;20(3):224–34.CrossRef

38.

Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–27.CrossRefPubMedPubMedCentral

Title: Dynamic change of the systemic immune inflammation index is a risk factor for patients with oropharyngeal cancer: a case control study and an additional HPV-status subgroup analysis
Authors: XiaoChuan Gan
QiTao Gou
Jing Zhu
Tao Zhang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Human Papillomavirus
Oropharyngeal Cancer
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01157-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dynamic change of the systemic immune inflammation index is a risk factor for patients with oropharyngeal cancer: a case control study and an additional HPV-status subgroup analysis

Abstract

Background

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Effects of dysregulated glucose metabolism on the occurrence and ART outcome of endometriosis

Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004–2022

Risk factors of prognosis in older patients with severe brain injury after surgical intervention

Nucleated red blood cells are a predictor of mortality in patients under extracorporeal membrane oxygenation

A systematic review, meta-analysis, and network analysis of diagnostic microRNAs in glaucoma

Intention to use maternal waiting home and its predictors among pregnant women in Ethiopia: systematic review and meta-analysis